RECK and cholangiocarcinoma: Recently, Fu et al. reported that tumor cell-derived EVs can deliver miR-210 to CCA cells, where miR-210 can target and inhibit the expression of RECK thus promoting the growth, metastasis, and chemoresistance in CCA [48].